Summary
The antitumor antibiotics have thus made a major impact on oncologic practice. The continued search for productive strains of these organisms should be encouraged; in addition, the activity and toxicity spectrum suggests the need for vigorous analogue development. An active anthracycline devoid of cardiotoxicity, a bleomycin with no effect on pulmonary tissue, an analogue of streptozoticin devoid of nephrotoxicity —these would be advances of inestimable benefit to the cancer patient of the future.
Similar content being viewed by others
References
Aisner, J., Esterhay, R. J., Jr., Wiernik, P. H. Treatment of oat cell carcinoma of the lung with cyclophosphamide, adriamycin, epipodophyllotoxin VP 16-213 and methanol extracted residue (MER) of BCG. Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 261 (1976)
Baehner, R. L., Bernstein, I. O., Higgins, G., McCreadie, S., Chard, R. L., Hammond, D.: Improved induction remission response in children with acute non-lymphocytic leukemia treated with daunomycin, 5-azacytidine, cytosine arabinoside, prednisone, and vincristine (D-ZAPO). Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. (in press, 1977)
Baker, L. H., Opipari, M. I., Izbicki, R. M.: Phase II study of mitomycin C, vincristine, and bleomycin in advanced squamous cell carcinoma of the uterine cervix. Cancer 38, 2222 (1976)
Benjamin, R. S., Hall, S. W., Burgess, M. A., Wheeler, W. L., Murphy, W. K., Blumenschein, G. R., Gottlieb, J. A.: A pharmacokinetically based phase I–II study of single dose actinomycin D (NSC-3053). Cancer treat. Rep. 60, 289 (1976)
Beretta, G., Bonnadonna, G., Cascinelli, N., Morabito, A., Veronesi, U.: Comparative evaluation of three combination regimens for advanced malignant melanoma; results of an international cooperative study. Cancer treat. Rep. 60, 33 (1976)
Billingham, M., Bristow, M., Mason, J., Friedman, M.: Endomyocardial biopsy findings in adriamycin treated patients. proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 281 (1976)
Blum, R. H., Carter, S. K.: Adriamycin, a new anticancer drug with significant clinical activity. Ann. intern. Med. 80, 249 (1974)
Blum, R. H., Carter, S. K., Agre, K.: A clinical review of bleomycin: a new antineoplastic agent. Cancer 31, 903 (1973)
Bonnadonna, G., de Lena, M., Monfardini, S., Bartoli, C., Bajetta, E., Beretta, G., Fossati-Bellani, F.: Clinical trials with bleomycin in lymphomas and solid tumors. Europ. J. Cancer 8, 205 (1972)
Bonnadonna, G., Zucilli, R. Monfardini, S. de Lena, M., Uslenghi, C.: Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36, 252 (1975)
Broder, L. E., Carter, S. K.: Pancreatic islet cell carcinoma II: results of therapy with streptozoticin in 52 patients. Ann. intern. Med. 79, 108 (1973)
Calendi, E., di Marco, A., Regiani, M., et al.: On physicochemical interactions between daunomycin and nucleic acids. Biochem. biophys. Acta (Amst.) 103, 25 (1965)
Carter, S. K., Wasserman, T. H.: The chemotherapy of urologic cancer. Cancer 36, 729 (1975)
Cohen, M. H., Hrushesky, W., Minna, J. D.: Chemotherapy response after initial treatment failure in small cell bronchogenic carcinoma. Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 112 (1976)
Cohen, M., Shaw, M. W., Craig, A. P.: The effects of streptonigrin in cultured human leucocytes. Proc. nat. Acad. Sci. (Wash.) 50, 16 (1963)
Cortez, E. P., Holland, J. F., Wang, J. J., Sinks, L. F., Blom, J., Senn, H., Bank, A., Glidewell, O.: Amputation and adriamycin in primary osteosarcoma. New Engl. J. Med. 291, 998 (1974)
Cryer, P. E., Hill, G. J., II: Pancreatic islet cell carcinoma with hypercalcemia and hypergastrinemia. Cancer 38, 2217 (1976)
Cvitkovic, E., Hayes, D., Golbey, R.: Primary combination chemotherapy (VAB III) for metastatic or unresectable germ cell tumors. Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 296 (1976)
Cvitkovic, E., Wittes, R., Golbey, R., Krakoff, I. H.: Primary combination chemotherapy (VAB II) for metastatic or unresectable germ cell tumors. Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 16, 174 (1975)
D'Angio, G. J., Evans, A. E., Breslow, N., Beckwith, B., Bishop, H., Feigl, P., Goodwin, W., Leapi, L. L., Sinks, L. F., Sutow, W., Tefft, M., Wolff, J. The treatment of Wilms' tumor: results of the National Wilms' tumor study. Cancer 38, 633 (1976)
de Vita V. T., Canellos, G. P., Moxley, J. H., III: A decade of combination therapy of advanced Hodgkin's disease. Cancer 30, 1495 (1972)
de Lena, M., Brambilla, C., Morabito, A., Bonnadonna, G.: Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer. Cancer 35, 1108 (1975)
Einhorn, L. H., Donohue, J. P.: Improved chemotherapy in disseminated testicular cancer. J. Urol. (Baltimore) 117, 65 (1977)
Farber, S.: Chemotherapy in the treatment of leukemia and Wilm's tumor. J. Amer. med. Ass. 198, 826 (1966)
Frei, E., III: The clinical use of actinomycin. Cancer Chemother. Rep. 58, 49 (1974)
Gale, R. P., Cline, M. J.: High remission induction rate in acute myeloid leukemia. Lancet 1977 I, 497
Ghavini, F., Exelby, P. R., d'Angio, G. J., Cham, W., Lieberman, P. H., Tam, C., Miki, V., Murphy, M. L.: Multidisciplinary treatment of embryonal rhabdomyosarcoma in children. Cancer 35, 667 (1975)
Gottlieb, J. A., Baker, L. H., Burgess, M. A., Sinkovics, J. G., Moon, T., Bodey, G. P., Rodrigues, V., Rivkin, S. E., Saiki, J., O'Bryan, R. M.: Sarcoma chemotherapy. In: Cancer chemotherapy, pp. 445–454. Chicago: Yearbook Medical Publishers 1975
Hammond, C. B., Parker, R. T.: Diagnosis and treatment of trophoblastic disease; a report from the Southeastern Regional Center. Obstet. and Gynec. 35, 132 (1970)
Holland, J. F., Glidewell, O.: Chemotherapy of acute lymphocytic leukemia of childhood. Cancer 30, 1480 (1972)
Hoogstraten, B., Chairman of the Southwest Oncology Group: Personal communication
Hoogstraten, B., George, S. L., Samal, B., Rivkin, S. E., Costanzi, J. J., Bonnet, J. D., Thigpen, T., Braine, H.: combination chemotherapy and adriamycin in patients with advanced breast cancer. Cancer 38, 13 (1976)
Hornback, N. B., Einhorn, L., Shidnia, H., Joe, B. T., Krause, M., Furnas, B.: Oat cell carcinoma of the lung. Cancer 37, 2658 (1976)
Jaffee, N., Frei, E., IV.: Osteogenia sarcoma: advances in treatment. CA-A Cancer Journal for Clinicians 26, 351 (1976)
Johnson, R. E., Brereton, H. D., Kent, C. H.: Small-cell carcinoma of the lung; attempt to remedy causes of past therapeutic failure. Lancet 1976 II, 289
Jones, B., Cuttner, J., Levy, R. N., Patterson, R. B., Kung, F., Pleuss, H. J., Falkson, G., Treat, C. L., Haurani, F., Burgert, E. O., Jr., Rosner, F., Carey, R. W., Lukens, J., Blom, J., Degnan, T. J., Wohl, H., Glidewell, O., Holland, J. F.: Daunorubicin (NSC-83142) versus daunorubicin plus prednisone (NSC-10023) versus daunorubicin plus vincristine (NSC-065) plus prednisone in advanced childhood acute leukemia. Cancer Chemother. Rep. 56, 729 (1972)
Jones, S. D., Durie, B. G. M., Salmon, S. E.: Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer 36, 90 (1975)
Junod, A., Lambert, A. E., Stauffacher, W., Renold, A. E.: Diabetogenic action of streptozoticin: relationship of dose to metabolic response. J. clin. Invest. 48, 2129 (1969)
Kaziro, Y., Kamiyama, M.: Mechanism of action of chromomycin A3. II: inhibition of RNA polymerase reaction. J. Biochem. (Tokyo) 62, 424 (1967)
Kennedy, B. J.: Metabolic and toxic effects of mithramycin during tumor therapy. Amer. J. Med. 49, 494 (1970)
Kennedy, B. J.: Mithramycin therapy in advanced testicular neoplasma. Cancer 26, 755 (1970)
Kennedy, B. J.: Mithramycin therapy in advanced neoplasms. Cancer 30, 755 (1970)
Kirk, J. M.: The mode of action of actinomycin D. Biochem. biophys. Acta (Amst.) 42, 167 (1960)
Kovach, J. S., Moertel, C. G., Ahmann, D. L., et al.: Phase I study of chromomycin A3 (NSC-58514). Cancer Chemother. Rep. 57, 341 (1973)
Kushnor, J. P., Hansen, V. L., Hammar, S. P.: Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin D and mithramycin. Cancer 34, 1577 (1975)
Lefrak, E. A., Oiťha, T., Rosenblum, S., Gottlieb, J. A.: Clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32, 302 (1973)
Lenaz, L., Page, J. A.: Cardiotoxicity of adriamycin and related anthracyclines. Cancer treat. Rev. 3, 111 (1976)
Lewis, J. L., Jr.: Chemotherapy of gestational choriocarcinoma. Cancer 30, 1517 (1972)
Li, M. C., Hertz, T., Spencer, D. B.: Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc. Soc. exp. Biol. (N.Y.) 93, 361 (1976)
Li, M. C., Whitmore, W. F., Golbey, R., Grabstadt, H.: Effects of combined crug therapy on metastatic cancer of the testis. J. Amer. med. Ass. 174, 1291 (1960)
Livingston, R. B., Moore, T. N.: Combined modality treatment of oat cell carcinoma of the lung. Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 152 (1976)
Loo, R. V., Vaitkevicius, V. R., Reed, M. L., Vaughn, C. B.: Phase I trial of porfiromycin (NSC-56410). Cancer Chemother. Rep. 51, 497 (1967)
MacDonald, J., Schein, P., Ueno, W., Woolley, P.: 5-fluorouracil (5-FU), mitomycin-C (MMC) and adriamycin (ADR)-FAM: a new combination chemotherapy program for advanced gastric carcinoma. Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 264 (1976)
McCredie, K. B., Hewlett, J. S., Kennedy, A.: The chemoimmunotherapy of acute leukemia (CIAL), a cooperative group study. Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 239 (1976)
McKelvey, E. M., Gottlieb, J. A., Wilson, H. E., Haut, A., Talley, R. W., Stephens, R., Lane, M., Gamble, J. F., Jones, S. E., Grozea, P. N., Gutterman, J., Coltman, D., Jr., Moon, T. E.: Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38, 1484 (1976)
Moertel, C. G., Reitmeier, R. J., Hahn, R. G.: Mitomycin C therapy in advanced gastrointestinal cancer. J. Amer. med. Ass. 204, 1045 (1969)
Muggia, F. M., Heinemann, H. O.: Hypercalcemia associated with neoplastic disease. Ann. intern. Med. 73, 281 (1970)
Nesbit, M. E.: Ewing's sarcoma. CA-A Cancer Journal for Clinicians 26, 174 (1976)
O'Bryan, R. M., Luce, J. K., Talley, R. W., Gottlieb, J. A., Baker, L. H., Bonnadonna, G.: Phase II evaluation of adriamycin in human neoplasia. Cancer 32, 1 (1973)
Olweny, C. L. M., Toya, T., Katongole-Mbidde, E., Lwanga, S. K., Owor, R., Kyalwazi, S., Vogel, C. L.: Treatment of Kaposi's sarcoma by combination of actinomycin-D, vincristine and imidazole carboxamide (NSC-45338): results of a randomized clinical trial. Int. J. Cancer 14, 649 (1974)
Osathanondh, R. O., Goldstein, D. P., pastorfide, G. B.: Actinomycin D as the primary agent for gestational trophoblastic disease. Cancer 36, 863 (1975)
Perlia, C. P., Gubisch, N. J., Wolter, J., Edelberg, D., Dederick, M. M., Taylor, S. G., III: Mithramycin treatment of hypercalcemia. Cancer 30, 389 (1970)
Pomeroy, T. C., Johnson, R. E.: Combined modality therapy of Ewing's sarcoma. Cancer 35, 36 (1975)
Rai, K. R., Holland, J. F., Glidewell, O.: Improvement in remission induction therapy of acute myelocytic leukemia. Proc. Amer. Ass. Cancer Res. 16, 265 (1975)
Ramirez, G., Weiss, A., The Central Oncology Group: A phase II study of adriamycin: 5 FU given weekly in the treatment of solid tumors. Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 248 (1976)
Reusses, F.: Mode of action of streptozoticin. J. Bact. 105, 580 (1971)
Reynolds, R. D., Fisher, J. I., Jensen, P. A., Pajak, T. F., Bateman, J. R.: Phase I alternate-day dose study of chromomycin A3. Cancer treat. Rep. 60, 1251 (1976)
Ryan, W. G., Schwartz, T. B., Northrop, G.: Treatment of Paget's disease with mithramycin: further experiences. Seminars in Drug Treatment 2, 57 (1972)
Samuels, M. L., Boyle, L. E., Holoye, P. Y., Johnson, D. E.: Intermittent versus continuous infusion bleomycin in testicular cancer: a comparison of response and survival in embryonal carcinoma (class 2) and teratocarcinoma (class 3 & 4). Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 98 (1976)
Samuels, M. L., Holoye, P. Y., Johnson, D. E.: Bleomycin combination chemotherapy in the management of testicular neoplasia. Cancer 36, 318 (1975)
Schein, P. S., de Vita, V. T., Hubbard, S., Chabner, B. A., Canellas, G. P., Berard, C., Young, R. C.: Bleomycin, adriamycin, cyclophosphamide, vincristine and prednisone (BACOP): combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann. intern. Med. 85, 417 (1976)
Schein, P. S., O'Connell, M. J., Blom, J., Hubbard, S., Magrath, I. T., Bergevin, P., Wiernik, P. H., Ziegler, J. L., de Vita, V. T.: Clinical antitumor activity and toxicity of streptozoticin (NSC-85998). Cancer 34, 993 (1974)
Selawry, O. S.: Polychemotherapy with adriamycin (NSC-123127) in bronchogenic carcinoma. Cancer Chemother. Rep. 6, 353 (1975)
Slayton, R. E., Shruder, B. I., Elias, E., Horton, J., Perlia, C. P.: New approach to the treatment of hypercalcemia. The effect of short-term treatment with mithramycin. Clin. Pharmacol. Ther. 12, 832 (1971)
Smith, J. P., Rutledge, F.: Advances in chemotherapy for gynecologic cancer. Cancer 36, 669 (1975)
Somerville, P. J., Evans, R. A.: Actinomycin D in the treatment of Paget's disease of bone. Med. J. Aust. 2, 13 (1975)
Sutow, W. W., Gehan, E. A., Vietti, T. J., Frias, A. E., Dyment, O. G.: Multidrug chemotherapy in primary treatment of osteosarcoma. J. Bone Jt Surg. 58-A, 629 (1976)
Suzuki, M., Nagai, R., Yamaki, H., Tanaha, N., Umezawa, H.: Mechanism of action of bleomycin: studies with growing culture of bacterial and tumor cells. J. Antibiot. (Tokyo) 21, 379 (1968)
Szybalski, W., Eyer, V. N.: Crosslinking of DNA by enzymatically or chemically activated mitomycins and porfiromycins, bifunctionally “alkylating” antibiotics. Fed. Proc. 23, 946 (1964)
Tattersall, M. H., Sodergren, J. E., Dengupta, S. K., Trites, D. J., Modest, E. J., Frei, E., III: Pharmacokinetics of actinomycin D in patients with malignant melanoma. Clin. Pharmacol. Ther. 17, 701 (1975)
Tranum, B., Hoogstraten, B.: Adriamycin in combination for treatment of breast cancer. Proc. Amer. Ass. Cancer Res., Amer. Soc. clin. Oncol. 17, 242 (1976)
Umezawa, H.: Principles of antitumor antibiotic therapy. In: Cancer medicine, pp. 817–826. Holland, J. F., Frei, E., III, (Eds.). Philadelphia: Lea & Febiger 1973
Vogel, C. L., Clements, D., Wanume, A. K., Toya, T., Primack, A., Kyalwazi, S.: Phase II clinical trials of BCNU (NSC-409962) and bleomycin (NSC-125066) in the treatment of Kaposi's sarcoma. Cancer Chemother. Rep. 57, 325 (1973)
Vogel, C. L., Primack, A., Dhru, D., Briers, P., Owor, R., Kyalwazi, S. K.: Treatment of Kaposi's sarcoma with a combination of actinomycin D and vincristine. Cancer 31, 1382 (1973)
Vogel, C. L., Templeton, C. J., Templeton, A. C., Taylor, J. F., Kyalwazi, S. K.: Treatment of Kaposi's sarcoma with actinomycin-D and cyclophosphamide: results of a randomized clinical trial. Int. J. Cancer 8, 136 (1971)
von Hoff, D. D., Rozencweig, M., Layard, M., Slavik, M., Muggia, F. M.: Daunomycin-induced cardiotoxicity in children and adults: a review of 110 cases. Amer. J. Med. 62, 200 (1976)
von Hoff, D. D., Rozencweig, M., Slavik, M.: Daunomycin: an antitumor antibiotic with activity in acute leukemia. Kanser 6, 1 (1976)
Weiss, A. J., Metter, G. E., Fletcher, W. S., Wilson, W. L., Grage, T. B., Ramirez, G.: Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer treat. Rep. 60, 813 (1976)
Yarbro, J. W., Barnum, C. P., Kennedy, B. J.: Mithramycin inhibition of RNA synthesis. Cancer Res. 26, 36 (1966)
Zbinden, G., Brandle, E.: Toxicologic screening of daunorubicin (NSC-82151), adriamycin (NSC-123127), and their derivatives in rats. Cancer Chemother. Rep. 59, 707 (1975)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Davis, H.L., von Hoff, D.D., Henney, J.E. et al. The role of antitumor antibiotics in current oncologic practice. Cancer Chemother. Pharmacol. 1, 83–90 (1978). https://doi.org/10.1007/BF00254041
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254041